177 related articles for article (PubMed ID: 37980167)
1. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.
Feng J; Wei X; Liu Y; Zhang Y; Li G; Xu Y; Zhou P; Zhang J; Han X; Zhang C; Zhang Y; Wang G
Aging (Albany NY); 2023 Nov; 15(22):13010-13040. PubMed ID: 37980167
[TBL] [Abstract][Full Text] [Related]
2. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
[TBL] [Abstract][Full Text] [Related]
5. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.
Yu S; Yang Y; Yang H; Peng L; Wu Z; Sun L; Wu Z; Yu X; Yin X
Sci Rep; 2023 May; 13(1):7560. PubMed ID: 37161008
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
7. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
8. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
[TBL] [Abstract][Full Text] [Related]
9. Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.
Liang C; Long K; Zheng W; Zhong R; Li Z; Zhu S; Gu S; Zhu C; Yang Y
Medicine (Baltimore); 2024 May; 103(18):e38028. PubMed ID: 38701314
[TBL] [Abstract][Full Text] [Related]
10. Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma.
Zhang Z; Wu L; Li J; Chen J; Yu Q; Yao H; Xu Y; Liu L
J Transl Med; 2022 Dec; 20(1):602. PubMed ID: 36522647
[TBL] [Abstract][Full Text] [Related]
11. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic biomarker:
Lai T; Peng T; Li J; Jiang Y; Liu K; Yu W; Yao N; Hu Y; Cao M; Liang J
Transl Cancer Res; 2023 May; 12(5):1145-1164. PubMed ID: 37304536
[TBL] [Abstract][Full Text] [Related]
13. ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.
Zhang C; Peng L; Gu H; Wang J; Wang Y; Xu Z
Sci Rep; 2023 Jan; 13(1):1583. PubMed ID: 36709331
[TBL] [Abstract][Full Text] [Related]
14. Integrated Bioinformatics and Experimental Analysis Identified TRIM28 a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Liver Hepatocellular Carcinoma.
Han J; Wang Y; Zhou H; Ai S; Wan D
Comput Math Methods Med; 2022; 2022():6267851. PubMed ID: 36238495
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.
Li S; Xue P; Diao X; Fan QY; Ye K; Tang XM; Liu J; Huang ZY; Tang QH; Jia CY; Xin R; Lv ZW; Liu JB; Ma YS; Fu D
J Adv Res; 2023 Dec; 54():133-146. PubMed ID: 36716957
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
17. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
[TBL] [Abstract][Full Text] [Related]
18. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
[TBL] [Abstract][Full Text] [Related]
19. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.
Wang J; Huang Z; Lu H; Zhang R; Feng Q; He A
Comput Math Methods Med; 2022; 2022():1258480. PubMed ID: 35242200
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
